FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry, has officially opened its expanded manufacturing facility in Hillerød, Denmark. This significant expansion doubles the site’s capacity, increasing the number of mammalian cell culture bioreactors from six to twelve, establishing it as the largest end-to-end biopharmaceutical manufacturing site in Europe. The groundbreaking ceremony for the expansion took place in 2020.

The expansion marks a major boost for the Danish life science sector, which has experienced substantial growth in recent years. Christian Houborg, site head and senior vice president for FUJIFILM Diosynth Biotechnologies, emphasized the company’s commitment to being a “Partner for Life,” supporting clients and patients globally. “This expansion demonstrates our vision to launch strong production capabilities in the global biopharmaceutical industry, ensuring the timely delivery of critical therapies to those in need worldwide,” stated Houborg.

Brian Mikkelsen, CEO of Dansk Erhverv, highlighted the Danish life science industry's impressive growth trajectory, citing increased exports and job creation. He praised FUJIFILM Diosynth Biotechnologies for its contribution to Danish society through production and growth. “One must tip their hat to FUJIFILM Diosynth Biotechnologies and their impressive journey, of which this expansion is the latest evidence. It is a company that contributes both through their production and growth to Danish society. That is something to celebrate,” said Mikkelsen.

Since 2019, the Hillerød site has grown from 750 to approximately 1,800 employees, with around 20% coming from abroad, representing over 70 nationalities. This growth underscores the company’s significant impact on the local economy and its appeal to a diverse workforce.

Lars Petersen, president and chief executive officer of FUJIFILM Diosynth Biotechnologies, emphasized that this expansion is just the beginning. The company has plans for further developments in the USA, United Kingdom, and Japan. “This first expansion of our site in Hillerød sets the stage for future developments, which will also extend to the USA, United Kingdom, and Japan,” Petersen stated. “By investing in state-of-the-art facilities on both sides of the Atlantic and prioritizing our employees, we are uniquely positioned to meet the needs of our partners and patients.”

Petersen reiterated the company’s “Partners for Life” strategy, emphasizing its dedication to supporting the production of life-changing medicines. “With our Partners for Life strategy, we are dedicated to fulfilling our promises and ensuring that our global network supports the production of life-changing medicines that improve patients’ lives,” he concluded.